Osteoporosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Primary osteoporotic patients (2) Patients who are treated with alendronate and alfacalcidol for more than 24 weeks and less than five years (3) Patients with informed of consent
Exclusion criteria
Exclusion criteria: (1) Patients who are diagnosed as contraindication of alendronate treatments (2) Patients who are diagnosed as contraindication of eldecalcitol treatments (3) Patients who are treated with glucocorticoid (4) Patients who have serum calcium levels of above 10.5mg/dL (5) Patients who have taken osteoporosis treatments other than alendronate and alfacalcidol (6) Patients who are inappropriate for this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of lumbar spine bone mineral density | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of total hip bone mineral density Number of fracture occurred Change of bone metabolic markers Safety | — |
Countries
Japan
Contacts
Tokyo Women's Medical University Medical Center East Department of Orthopaedic Surgery